Background and Aims. Chemotherapy of colorectal liver metastases can induce hepatotoxicity in noncancerous liver. We describe these lesions and assess risk factors and impacts on postresection morbidity and mortality in naive patients to chemotherapy before the era of bevacizumab. Methods. Noncancerous liver tissue lesions were analysed according to tumour, chemotherapy, surgery, and patient characteristics. Results. Fifty patients aged 62 ± 9.3 years were included between 2003 and 2007. Thirty-three (66%) received chemotherapy, with Folfox (58%), Folfiri (21%), LV5FU2 (12%), or Xelox (9%) regimens. Hepatotoxicity consisted of 18 (36%) cases of severe sinusoidal dilatation (SD), 13 (26%) portal fibrosis, 7 (14%) perisinusoidal fibrosis (PSF), 6 (12%) nodular regenerative hyperplasia (NRH), 2 (4%) steatosis >30%, zero steatohepatitis, and 16 (32%) surgical hepatitis. PSF was more frequent after chemotherapy (21% versus 0%, ), especially LV5FU2 ( ). SD was associated with oxaliplatin (54.5% versus 23.5%, ) and low body mass index ( ). NRH was associated with oxaliplatin ( ) and extensive resection ( ). No impact on mortality and morbidity was observed, apart postoperative elevation of bilirubin levels in case of PSF ( ), longer hospitalization in case of surgical hepatitis ( ), and greater blood loss in case of portal fibrosis ( ). Conclusions. Chemotherapy of colorectal liver metastases induces sinusoidal dilatation related to oxaliplatin and perisinusoidal fibrosis related to 5FU, without any impact on postoperative mortality. 1. Introduction Synchronous or metachronous liver metastases (LMs) complicate the course of colorectal cancers (CRCs) in 40% of cases. Surgical resection of LM is the standard treatment, allowing a 5-year survival rate estimated to be between 25 and 44% [1]. Over the past decade, substantial improvement has been obtained in terms of systemic chemotherapy for CLM including perioperative [2] and induction [3] chemotherapies. For patients with initially unresectable disease, induction chemotherapy is offered with a goal of converting these patients to a resectable situation with a 5-year survival rate after resection reaching 35% [1, 3]. However, regardless of its benefit, subsequent toxicity on the nontumorous liver parenchyma has been recently reported in this setting. Various authors have reported increased morbidity and mortality rates after liver resection in patients who received preoperative oxaliplatin or irinotecan-based regimens [4–6]. Several arguments support that irinotecan-based chemotherapy is involved in a
References
[1]
M. Minagawa, M. Makuuchi, G. Torzilli et al., “Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results,” Annals of Surgery, vol. 231, no. 4, pp. 487–499, 2000.
[2]
B. Nordlinger, H. Sorbye, B. Glimelius et al., “Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial,” The Lancet, vol. 371, no. 9617, pp. 1007–1016, 2008.
[3]
R. Adam, V. Delvart, G. Pascal et al., “Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival,” Annals of Surgery, vol. 240, no. 4, pp. 644–658, 2004.
[4]
J. Y. Douillard, D. Cunningham, A. D. Roth et al., “Irinotecan combined with fluorouracil compared with fluorouracil alone. as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial,” The Lancet, vol. 355, no. 9209, pp. 1041–1047, 2000.
[5]
A. Falcone, S. Ricci, I. Brunetti et al., “Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico nord ovest,” Journal of Clinical Oncology, vol. 25, no. 13, pp. 1670–1676, 2007.
[6]
A. Brouquet and B. Nordlinger, “Neoadjuvant therapy of colorectal liver metastases: lessons learned from clinical trials,” Journal of Surgical Oncology, vol. 102, no. 8, pp. 932–936, 2010.
[7]
J. N. Vauthey, T. M. Pawlik, D. Ribero et al., “Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases,” Journal of Clinical Oncology, vol. 24, no. 13, pp. 2065–2072, 2006.
[8]
D. Zorzi, A. Laurent, T. M. Pawlik, G. Y. Lauwers, J. N. Vauthey, and E. K. Abdalla, “Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases,” British Journal of Surgery, vol. 94, no. 3, pp. 274–286, 2007.
[9]
F. G. Fernandez, J. Ritter, J. W. Goodwin, D. C. Linehan, W. G. Hawkins, and S. M. Strasberg, “Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases,” Journal of the American College of Surgeons, vol. 200, no. 6, pp. 845–853, 2005.
[10]
O. Soubrane, A. Brouquet, S. Zalinski et al., “Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome,” Annals of Surgery, vol. 251, no. 3, pp. 454–460, 2010.
[11]
L. Rubbia-Brandt, V. Audard, P. Sartoretti et al., “Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer,” Annals of Oncology, vol. 15, no. 3, pp. 460–466, 2004.
[12]
D. Fuks, M. C. Cook, O. Bréhant et al., “Colorectal carcinoma with potentially resectable metastases: factors associated with the failure of curative schedule,” Gastroenterologie Clinique et Biologique, vol. 32, no. 4, pp. 390–400, 2008.
[13]
T. Aloia, M. Sebagh, M. Plasse et al., “Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 4983–4990, 2006.
[14]
D. Ribero, H. Wang, M. Donadon et al., “Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases,” Cancer, vol. 110, no. 12, pp. 2761–2767, 2007.
[15]
M. Klinger, S. Eipeldauer, S. Hacker et al., “Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectalcancer liver metastases,” European Journal of Surgical Oncology, vol. 35, no. 5, pp. 515–520, 2009.
[16]
P. Pessaux, F. Panaro, S. Casnedi et al., “Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study,” European Journal of Surgical Oncology, vol. 36, no. 6, pp. 575–582, 2010.
[17]
P. Pessaux, M.-P. Chenard, P. Bachellier, and D. Jaeck, “Consequences of chemotherapy on resection of colorectal liver metastases,” Journal of Visceral Surgery, vol. 147, no. 4, pp. e193–201, 2010.
[18]
G. Lopes, J. Quesada, E. Ahn, A. Flores, A. Ribeiro, and C. M. Rocha-Lima, “Oxaliplatin and fixed-rate infusional gemcitabine in the second-line treatment of patients with metastatic colon cancer: final results of a phase II trial prematurely closed as a result of poor accrual,” Clinical Colorectal Cancer, vol. 6, no. 9, pp. 641–645, 2007.
[19]
A. Iguchi, R. Kobayashi, M. Yoshida et al., “Vascular endothelial growth factor (VEGF) is one of the cytokines causative and predictive of hepatic veno-occlusive disease (VOD) in stem cell transplantation,” Bone Marrow Transplantation, vol. 27, no. 11, pp. 1173–1180, 2001.
[20]
L. D. Deleve, X. Wang, J. Tsai, G. Kanel, S. Strasberg, and Z. A. Tokes, “Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition,” Gastroenterology, vol. 125, no. 3, pp. 882–890, 2003.
[21]
J. Belghiti, O. A. Guevara, R. Noun, P. F. Saldinger, and R. Kianmanesh, “Liver hanging maneuver: a safe approach to right hepatectomy without liver mobilization,” Journal of the American College of Surgeons, vol. 193, no. 1, pp. 109–111, 2001.
[22]
D. Dindo, N. Demartines, and P. A. Clavien, “Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey,” Annals of Surgery, vol. 240, no. 2, pp. 205–213, 2004.
[23]
F. Cauchy, B. Aussilhou, S. Dokmak et al., “Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases,” Annals of Surgery, vol. 256, pp. 746–754, 2012.
[24]
S. Balzan, J. Belghiti, O. Farges et al., “The “50-50 criteria” on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy,” Annals of Surgery, vol. 242, no. 6, pp. 824–829, 2005.
[25]
C. Paugam-Burtz, S. Janny, D. Delefosse et al., “Prospective validation of the “fifty-fifty” criteria as an early and accurate predictor of death after liver resection in intensive care unit patients,” Annals of Surgery, vol. 249, no. 1, pp. 124–128, 2009.
[26]
P. Bedossa, T. Poynard, S. Naveau, E. D. Martin, H. Agostini, and J. C. Chaput, “Observation variation in assessment of liver biopsies of alcoholic patients,” Alcoholism, vol. 12, no. 1, pp. 173–178, 1988.
[27]
D. E. Kleiner, E. M. Brunt, M. Van Natta et al., “Design and validation of a histological scoring system for nonalcoholic fatty liver disease,” Hepatology, vol. 41, no. 6, pp. 1313–1321, 2005.
[28]
P. Latry, P. Bioulac-Sage, E. Echinard et al., “Perisinusoidal fibrosis and basement membrane-like material in the livers of diabetic patients,” Human Pathology, vol. 18, no. 8, pp. 775–780, 1987.
[29]
P. Bedossa and T. Poynard, “An algorithm for the grading of activity in chronic hepatitis C,” Hepatology, vol. 24, no. 2, pp. 289–293, 1996.
[30]
N. J. Petrelli, J. Abbruzzese, P. Mansfield, and B. Minsky, “Hepatic resection: the last surgical frontier for colorectal cancer,” Journal of Clinical Oncology, vol. 23, no. 20, pp. 4475–4477, 2005.
[31]
G. D. Leonard, B. Brenner, and N. E. Kemeny, “Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 2038–2048, 2005.
[32]
D. G. Blazer III, Y. Kishi, D. M. Maru et al., “Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases,” Journal of Clinical Oncology, vol. 26, no. 33, pp. 5344–5351, 2008.
[33]
O. Farges, B. Cherciu, E. Chelbi et al., “Non tumorous liver injuries in patients with colorectal cancer treated by surgical resection: frequency and consequences,” Gastroentérologie Clinique et Biologique, vol. 31, article A26, 2007.
[34]
M. Karoui, C. Penna, M. Amin-Hashem et al., “Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases,” Annals of Surgery, vol. 243, no. 1, pp. 1–7, 2006.
[35]
T. M. Pawlik, K. Olino, A. L. Gleisner, M. Torbenson, R. Schulick, and M. A. Choti, “Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome,” Journal of Gastrointestinal Surgery, vol. 11, no. 7, pp. 860–868, 2007.
[36]
C. Julie, M. P. Lutz, D. Aust et al., “Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC Intergroup phase III study 40983,” Journal of Clinical Oncology, vol. 25, abstract A241, 2007.
[37]
L. D. DeLeve, H. M. Shulman, and G. B. McDonald, “Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease),” Seminars in Liver Disease, vol. 22, no. 1, pp. 27–41, 2002.
[38]
E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999.
[39]
S. Izumi, M. Nishiuchi, Y. Kameda et al., “Laparoscopic study of peliosis hepatis and nodular transformation of the liver before and after renal transplantation: natural history and aetiology in follow-up cases,” Journal of Hepatology, vol. 20, no. 1, pp. 129–137, 1994.
[40]
K. E. Behrns, G. G. Tsiotos, N. F. DeSouza, M. K. Krishna, J. Ludwig, and D. M. Nagorney, “Hepatic steatosis as a potential risk factor for major hepatic resection,” Journal of Gastrointestinal Surgery, vol. 2, no. 3, pp. 292–298, 1998.
[41]
J. Belghiti, K. Hiramatsu, S. Benoist, P. P. Massault, A. Sauvanet, and O. Farges, “Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection,” Journal of the American College of Surgeons, vol. 191, no. 1, pp. 38–46, 2000.
[42]
D. A. Kooby, Y. Fong, A. Suriawinata et al., “Impact of steatosis on perioperative outcome following hepatic resection,” Journal of Gastrointestinal Surgery, vol. 7, no. 8, pp. 1034–1044, 2003.
[43]
P. J. Kneuertz, S. K. Maithel, C. A. Staley, and D. A. Kooby, “Chemotherapy-associated liver injury: impact on surgical on management of colorectal cancer liver metastases,” Annals of Surgical Oncology, vol. 18, pp. 181–190, 2011.
